Market Cap
₹21,122 Cr.
P/E
35.79
Quick View
  • 1d
  • 1m
  • 6m
  • YTD
  • 1y
  • 3y
  • 5y
  • 10y
  • max

Company Timeline

Forensics
Other Income
Other Income is not affecting ratios of the company
Capex vs ROCE
Company has made significant capex which might be affecting its ROCE
Pledge
Promoters have not pledged a significant portion of their holding
Revenue Recognition
Company is converting accounting profit to cash
Depreciation Effect
Depreciation accounting is not leading to increase in profits
Contingent Liabilities
Company does not have significant contingent liabilities
Retail Holding
Retail has been selling the stock which is usually a good time to buy
Share price
Share price has increased over last 10 years due to earnings
ROE
Asset Turnover is responsible for ROE increase over last 10 years
Working Capital
Working Capital of the company seems to be under control
Debt
Company should not have issues servicing its debt
Promoter Holding
Promoter has not sold any shares in the last 90 days
Current vs Historic Valuation
Company is trading at a premium to 3 year historic valuations
ROE
Latest
7.83%
3yr Average
13.47%
5yr Average
17.53%
Net Profit Margin
Latest
6.05%
3yr Average
12.38%
5yr Average
13.99%
ROCE
Latest
9.85%
3yr Average
15.72%
5yr Average
19.16%
Debt to Equity
Latest
0.15
3yr Average
0.12
5yr Average
0.26
Market Share
1.40% (as of Jun 23)
Anti - Diabetes - Market Share
2.10% (as of Jun 23)
Anti-Infectives - Market Share
0.14% (as of Nov 21)
Anti-Malarial - Market Share
0.01% (as of Nov 21)
Antineo Plastic - Market Share
0.26% (as of Nov 21)
Blood Related - Market Share
1.80% (as of Jun 23)
Cardiovascular - Market Share
4.20% (as of Jun 23)
Cold & Cough Medication Market Share
0.20% (as of Jun 23)
Dermatology - Market Share
0.02% (as of Nov 21)
Endocrinology - Market Share
1.20% (as of Jun 23)
Gastro-Intestinal - Market Share
3.10% (as of Jun 23)
Gynecology - Market Share
0.10% (as of Nov 21)
Neurological - Market Share
2% (as of Jun 23)
Ophthalmology - Market Share
0.83% (as of Nov 21)
Pain - Market Share
1.50% (as of Jun 23)
Pharmaceutical Sector - Market Share
1.85% (as of Nov 21)
Respiratory - Market Share
3.67% (as of Nov 21)
Urology - Market Share
0.80% (as of Jul 22)
Vitamin & Dietary Supplements - Market Share
Show more
Revenue mix

Product Wise Break-Up

locked
Source
|
Latest
|
locked
Historic

Product Wise Break-Up -Formulations

locked
Source
|
Latest
|
locked
Historic

Product Wise Break-Up -Domestic Branded Formulation Business

locked
Source
|
Latest
|
locked
Historic

Location Wise Break-Up -API

locked
Source
|
Latest
|
locked
Historic

Location Wise Break-Up -Formulations

locked
Source
|
Latest
|
locked
Historic

Location Wise Break-Up

locked
Source
|
Latest
|
locked
Historic

Therapeutic Area Break-Up

locked
Source
|
Latest
|
locked
Historic

Acute vs Chronic -Formulations

locked
Source
|
Latest
|
locked
Historic
Show more
Operational Metrics

    Select a Metric
    • US DMF Filings (.)
    • Number of ANDA's Filed in Europe
    • Number of ANDA's Approved in Europe
    • Number of ANDA's Filed in Canada
    • Number of ANDA's Approved by Canada
    • Number of ANDA's Filed in Australia
    • Number of ANDA's Approved by Australia
    • Number of ANDA's Filed in USA (.)
    • Number of ANDA's Approved By USFDA (.)
    • Number of ANDA's Filed in Latam
    • Number of ANDA's Approved by Latam
    • Number of ANDA's Filed in South Africa
    • Number of ANDA's Approved by South Africa
    • R&D as a % of Total Sales (%)
    Peer Comparison
    Brands
    Azithral
    Tellzy
    Zeet
    Suppliers
    Company Filing
    Show Previous Years
    Discussions & Analysis